EUCTR2018-003222-92-NL进行中（未招募）1 期
Dendritic cells loaded with allogeneic tumor cell lysate (PheraLys™) in surgically resected pancreatic cancer patients (REACtiVe Trial) - REACtiVe
适应症
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
- Erasmus MC
- 入组人数
- 26
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •Surgically resected pancreatic cancer.
- •Completed post-operative standard treatment. Patients who did not complete standard of care due to toxicity or who are not able to start standard of care due to specific reasons are allowed to participate in the study after approval of the coordinating investigator.
- •No disease activity as assessed by radiological imaging.
- •Patients must be at least 18 years old and must be able to give written informed consent.
- •Patients must be ambulatory (WHO-ECOG performance status 0,1 or 2) and in stable medical condition.
- •Patients must have normal organ function and adequate bone marrow reserve: absolute neutrophil count >1.0 x 10E9/l, platelet count > 100 x 10E9/l, and Hb > 6.0 mmol/l (as determined during screening).
- •Women of childbearing potential must have a negative serum pregnancy test at screening and a negative urine pregnancy test just prior to the first study drug administration on Day 1, and must be willing to use an effective contraceptive method (intrauterine devices, hormonal contraceptives, contraceptive pill, implants, transdermal patches, hormonal vaginal devices, infusions with prolonged release) or true abstinence (when this is in line with the preferred and usual lifestyle)* during the study and for at least 12 months after the last study drug administration. *True abstinence is acceptable when this is in line with the preferred and usual lifestyle of the subject. Periodic abstinence (such as calendar, ovulation, symptothermal, post-ovulation methods) and withdrawal are not acceptable methods of contraception.
- •Men must be willing to use an effective contraceptive method (e.g. condom, vasectomy) during the study and for at least 12 months after the last study drug administration.
- •Positive DTH skin test (induration > 2mm after 48 hrs) against at least one positive control antigen tetanus toxoid (see section 8.3 for DTH skin
- •test procedure).
- •Ability to return to the hospital for adequate follow-up as required by this protocol.
- •Written informed consent according to ICH-GCP.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 20
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 6
排除标准
- •Medical or psychological impediment to probable compliance with the protocol.
- •Current or previous treatment with immunotherapeutic agents.
- •Current use of steroids (or other immunosuppressive agents). Patients must have had 6 weeks of discontinuation and must stop any such treatment during the time of the study. Prophylactic usage of dexamethasone during chemotherapy is excluded from this 6 weeks interval.
- •Prior malignancy except adequately treated basal cell or squamous cell skin cancer, superficial or in-situ cancer of the bladder or other cancer for which the patient has been disease-free for five years.
- •Serious concomitant disease, or active infections.
- •History of autoimmune disease or organ allografts (or with active acute or chronic infection, including HIV and viral hepatitis).
- •Serious intercurrent chronic or acute illness such as pulmonary disease (asthma or COPD), cardiac disease (NYHA class III or IV), hepatic disease or other illness considered by the study coordinator to constitute an unwarranted high risk for investigational DC treatment.
- •Known allergy to shell fish (may contain keyhole limpet hemocyanin (KLH).
- •Pregnant or lactating women.
- •Inadequate vein access to perform leukapheresis.
- •Concomitant participation in another clinical trial (except participation in a biobank study).
- •An organic brain syndrome or other significant psychiatric abnormality which would compromise the ability to give informed consent, and preclude participation in the full protocol and follow-up.
- •Absence of assurance of compliance with the protocol. Lack of availability for follow-up assessments.
研究者
相似试验
已完成
不适用
Dendritic Cells loaded with allogeneic tumor lysate (MesoPher) in combination with a CD40 agonist (Mitazalimab) in metastatic pancreatic disease (REACtiVe-2 Trial)NL-OMON52234Erasmus MC, Universitair Medisch Centrum Rotterdam30
招募中
不适用
Dendritic Cells loaded with allogeneic tumor lysate (MesoPher) in combination with a CD40 agonist (Mitazalimab) in metastatic pancreatic diseaseNL-OMON27591Department of Pulmonary Medicine, Erasmus MC18
已完成
1 期
Dendritic cell immunotherapy for patients with resected pancreatic cancer<p>Pancreatic cancer, alvleesklierkanker, pancreascarcinoom</p>10015674NL-OMON28791Erasmus Medical Center10
进行中（未招募）
不适用
Vaccine with dendritic cells pulsed tumoral cell line or with autologue tumor in patients with kidney carcinoma - NDkidney carcinomaMedDRA version: 6.1Level: PTClassification code 10038415EUCTR2006-004751-38-ITOSPEDALE ONCOLOGICO DI BARI
已完成
1 期
Dendritic cell-based tumor-specific immunotherapy against malignant brain tumor - Phase I clinical trialMalignant brain tumor (malignant glioma)JPRN-UMIN000000914Shizuoka Cancer Center12